• Skip to main content
  • Skip to footer

bioSyntagma

Eliminating trial-and-error cancer treatments

  • Technology
  • Company
  • News
  • Contact

General

Jan 29 2019

bioSyntagma Awarded “Best Oncology-Focused Precision Medicine Company 2018”

bioSyntagma has been awarded “Best Oncology-Focused Precision Medicine Company 2018” by Global Health and Pharma, a UK-based publication that recognizes global companies for improving public health, enhancing patient care, and lowering healthcare costs.  This award follows several commercial milestones with strategic partners and Big Pharma using bioSyntagma’s beta-instruments to offer biomarker discovery services.

Striving to eliminate-trial-and-error cancer treatments through predictive analytics and novel diagnostic tools, bioSyntagma has developed a suite of AI-enabled technologies that collectively create the Molecular Fingerprint™.  “The Molecular Fingerprint (mPrint) is how personalized medicine transitions from a buzzword to reality,” said David Richardson, CEO of bioSyntagma.  “It’s not about a specific drug but about combinations of therapies that precisely match the state of a person’s disease. We are honored GHP recognizes the impact of our work.”

The Arizona State University spin-out company and current client at the Center for Entrepreneurial Innovation is now building more instruments to support broader enrollment in their Early Access Program to provide spatial profiling services.  This will enable bioSyntagma to support data acquisition for joint discovery and predictive analytic applications.

A full list of The GHP Technology Awards 2018 winners can be accessed at https://www.ghp-news.com/technology-awards-2018.

About bioSyntagma

bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. Its suite of platform technologies enables comprehensive, multi-omic and spatial profiling of tissues to get a complete and informed understanding of a patient’s cancer so they can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance.  bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.

Written by bioSyntagma · Categorized: General

Oct 30 2018

bioSyntagma Announced as Semifinalist in the Arizona Commerce Authority’s Fall 2018 Arizona Innovation Challenge

Phoenix, AZ (October 30, 2018) – The Arizona Commerce Authority (ACA) today announced 25 semifinalists in the Fall 2018 round of the Arizona Innovation Challenge, a bi-annual business plan competition for promising early-stage companies in high-growth industries.

As many as ten recipients in each round will receive up to $150,000 each in capital to grow their businesses, advancing innovation and technology commercialization opportunities in Arizona. The funding for each awardee will be released in phases, according to milestones that are defined by participation in the Venture Ready mentorship program.

“We’ve implemented enhancements to the Arizona Innovation Challenge in order to support a greater number of innovative Arizona startups in commercializing their technologies,” said Sandra Watson, President & CEO of the Arizona Commerce Authority. “These modifications will also ensure all participants receive the Venture Ready mentorship experience, a rigorous process designed to equip them with the skills they’ll need as they continue scaling their ventures.”

A total of 104 applications were received for the Fall 2018 round from companies across Arizona. The judges assessed each application on a set of criteria including technology potential, marketing strategy, quality of management team and economic impact.

Every applicant that meets the Challenge’s eligibility requirements receives constructive feedback generated from the rigorous online evaluation and scoring process. Semifinalists will participate in another round of judging and 20 finalists will be selected to continue on to the next round of the Challenge. Up to ten awardees will then be selected from that group of finalists.

About bioSyntagma

bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. Its suite of platform technologies enables comprehensive, multi-omic and spatial profiling of tissues to get a complete and informed understanding of a patient’s cancer so they can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance.  bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.

Written by bioSyntagma · Categorized: General

Mar 20 2018

bioSyntagma Awarded $200k Phase I NIH SBIR Grant to Advance Development of a Next-Generation Single-Cell Biomarker Discovery Platform

Phoenix, AZ (March 20, 2018) — bioSyntagma, a precision medicine company, has been awarded  a nearly $200,000 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop a new platform for mapping multi-omic biomarkers from single-cells in cancer patient biopsies.  bioSyntagma’s Principal Scientist, Dmitry Derkach, M.D., Ph.D., is the Principal Investigator for the project.

The award provides funding to develop a spatial, multi-omic single-cell analysis platform that can provide vast amounts of information about the tumor microenvironment.

Last year, more than $45B was spent worldwide on targeted therapies in oncology.  However, nearly every patient that receives a targeted therapy will eventually develop resistance to it.  Strategies to overcome acquired drug resistance are crucial to the success of targeted therapies.

“This technology is key to truly enabling personalized medicine,” says Dr. Derkach.  “Understanding the tumor microenvironment will help make better treatments, help screen patients to identify personal treatments for them, and identify options to overcome resistance in patients.  This is how we make personalized medicine happen.”

About bioSyntagma

bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. Its suite of platform technologies enables comprehensive, multi-omic and spatial profiling of tissues to get a complete and informed understanding of a patient’s cancer so they can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance.  bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. For more information about NIH and its programs, visit www.nih.gov.

Research performed will be supported by the National Cancer Institute of the National Institutes of Health under Award Number R43CA228712. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Written by bioSyntagma · Categorized: General

Feb 06 2018

bioSyntagma Awarded National Science Foundation Phase II Small Business Innovation Research Grant

Phoenix, AZ (February 6, 2019 — bioSyntagma, LLC, a developer of life science tools for single and multi-cell analysis announced today it has been has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant of $735,139. Upon completion of the Phase I SBIR, bioSyntagma successfully demonstrated feasibility of their technology, the LightStream FloCellTM, which visually maps genetic information across a tissue and correlates this information with molecular measurements in a high-throughput and automated fashion, with the ultimate goal of enabling personalized medicine. Phase II funding will be used to continue product development and launch commercialization.

bioSyntagma will produce their first beta instruments by implementing their technology into a high-throughput commercial product.  They will hire additional staff to support development as well as create artificial intelligence algorithms to mine the data produced on these instruments.  This will allow bioSyntagma to commercially launch their platform technology for discovery and implementation of precision medicines.

About the NSF’s Small Business Programs: America’s Seed Fund powered by NSF awards nearly $190 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.5 million in non-dilutive funds to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $7.5 billion that supports fundamental research and education across all fields of science and engineering. For more information, visit seedfund.nsf.gov.

Written by bioSyntagma · Categorized: General

May 30 2017

bioSyntagma Core Patent for Cancer Research Awarded by USPTO

Phoenix, AZ — bioSyntagma, LLC announced today that the United States Patent and Trademark Office fully issued patent # 15/099,121 for “Method and Apparatus for Extracting and Collecting Single Cells from Formalin-Fixed Paraffin Embedded Tissues,” which bioSyntagma has exclusively licensed from Arizona Technology Enterprises (AzTE). This patent is the foundational technology for the company’s unique microfluidic chip technology, the Light Stream FloCell™. The LightStream FloCell™ allows researchers to examine patient and research tissues to understand how disease-causing cells interact with each other. bioSyntagma’s technology is seen as fundamental to understanding diseases such as cancer, diabetes, and Alzheimer’s by illuminating key cellular interactions in these disease states.

bioSyntagama was founded by three of the named inventors on the patent: David Richardson, Dmitry Derkach, MD, Ph.D., and Colleen Ziegler. bioSyntagma, a Center for Entrepreneurial Innovation client located on the GateWay Community College campus, licensed the patent exclusively from Arizona Technology Enterprises (AzTE). Arizona Technology Enterprises (AzTE) is the exclusive intellectual property management and technology transfer organization for Arizona State University.

“Colleen, Dmitry, and I are the inventors of this device and founded bioSyntagma based on our ability to provide a level of resolution on tissue samples like patient biopsies down to single cells, which provides insight into serious illnesses like cancer. Our technology is positioned to enable doctors and researchers to understand why some people do not respond to cancer treatments, or why some that initially respond become resistant and relapse. We are thrilled that the USPTO recognized the unique contribution this technology can make and awarded a patent for which we are the exclusive license holder from AzTE,” said David Richardson, CEO of bioSyntagma.

The LightStream FloCell™, or tissue chip, allows scientists, researchers, clinicians, and laboratory technologists to identify single cells, or areas of interests from routine biopsy tissues and move those cells using the tissue chip to a standard collection tube for further analysis. This capability can help unlock the underlying mechanisms of diseases such as cancer, where differences in cells can cause resistance to even the latest cancer therapies, as well as, diabetes and other autoimmune diseases like arthritis, and neurological disorders like Alzheimer’s.

About bioSyntagma

bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. Its suite of platform technologies enables comprehensive, multi-omic and spatial profiling of tissues to get a complete and informed understanding of a patient’s cancer so they can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance.  bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance t

Written by bioSyntagma · Categorized: General

Footer

Home Technology Company News Contact


2113 S 48th St. Ste 103, Tempe, AZ 85282
info@biosyntagma.com
© 2021 bioSyntagma. All Rights Reserved.